96 related articles for article (PubMed ID: 7737253)
1. A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.
Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
Eur Urol; 1994; 26 Suppl 1():1-2. PubMed ID: 7737253
[No Abstract] [Full Text] [Related]
2. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group.
Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
Eur Urol; 1995; 27(1):43-6. PubMed ID: 7744141
[TBL] [Abstract][Full Text] [Related]
3. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
4. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
[TBL] [Abstract][Full Text] [Related]
5. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group.
Fernandez del Moral P; Dijkman GA; Debruyne FM; Witjes WP; Kolvenbag GJ
Urology; 1996 Dec; 48(6):894-900. PubMed ID: 8973673
[TBL] [Abstract][Full Text] [Related]
6. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
7. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial.
Fontana D; Mari M; Martinelli A; Boccafoschi C; Magno C; Turriziani M; Maymone SS; Cunico SC; Zanollo A; Montagna G; Frongia M; Jacobellis U
Urol Int; 2003; 70(4):316-20. PubMed ID: 12740498
[TBL] [Abstract][Full Text] [Related]
8. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
9. [Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].
Haefliger JM
Helv Chir Acta; 1992 Oct; 59(3):477-83. PubMed ID: 1464545
[TBL] [Abstract][Full Text] [Related]
10. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP; Sotarauta M
Cancer; 1993 Dec; 72(12 Suppl):3878-9. PubMed ID: 8252508
[No Abstract] [Full Text] [Related]
13. A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.
Emtage LA; Trethowan C; Kelly K; Arkell D; Wallace DM; Hughes M; Hay A; Blacklock R; Jones M; Rouse A
Prog Clin Biol Res; 1989; 303():47-52. PubMed ID: 2528739
[No Abstract] [Full Text] [Related]
14. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.
Debruyne FM; Dijkman GA; Lee DC; Witjes WP; del Moral F; Karthaus HF; van der Mejden AP; Plasman JW; Pull HC; Kums JJ; Idema JG; Hoefakker JW; Heijbroek RP; Kil PJ; Khoe GS
J Urol; 1996 Apr; 155(4):1352-4. PubMed ID: 8632572
[TBL] [Abstract][Full Text] [Related]
15. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
[TBL] [Abstract][Full Text] [Related]
16. [Quality of life following endocrine therapy for advanced prostate cancer: a comparative study between LH-RH agonist 1-month depot and 3-month depot].
Namiki S; Ishidoya S; Saito S; Mitsukawa S; Suzuki Y; Numata I; Arai Y
Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):631-7. PubMed ID: 18697469
[TBL] [Abstract][Full Text] [Related]
17. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Peeling WB
Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
[TBL] [Abstract][Full Text] [Related]
18. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
Di Silverio F; Serio M; Costantini A
J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
[No Abstract] [Full Text] [Related]
19. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
20. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
